KUCHING: The Serian area Health office in Sarawak is taking measures to curb hepatitis B in the division, says state Deputy ...

HBV and HCV infections in children are chronic infections, and are often asymptomatic but also have possible negative outcomes. Most children with chronic hepatitis B or C are expected to ...

Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program; ACE1831 is an allogeneic gamma delta T cell therapy candidate targetin ...

Anti-HBs is a neutralizing antibody and its presence suggests the recovery from hepatitis B and confers a long-term protective immunity against HBV infection. In addition, it is the only ...

Indaptus’ Decoy product candidates have also produced meaningful single agent activity against chronic hepatitis B virus (HBV) and chronic human ... of the combination of BeiGene’s anti-PD-1 antibody, ...

Encouraging Preclinical Data: Decoy20 has produced efficacy in preclinical studies across a variety of tumor types and in combination with four different classes of existing drugs, demonstrating both ...

Q3 2024 Earnings Call Transcript November 7, 2024 Dynavax Technologies Corporation beats earnings expectations. Reported EPS ...

Arbutus has moved into Part 3 of this clinical trial which evaluates repeat dosing of AB-101 for 28 days in patients with cHBV and expects to report preliminary data in the first half of next year.

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

They successfully demonstrated detection of HBV DNA hybridization with 10.8 fF/log [DNA] sensitivity ... Detection antibodies bound to the antigen, and the antigen bound to the capture antibody ...

The global hepatitis B diagnostic tests market is on the cusp of substantial expansion, driven by a combination of increasing disease incidence, heightened global awareness campaigns, and rapid ...